MX2016016756A - Terapia con células madre en patologías endometriales. - Google Patents

Terapia con células madre en patologías endometriales.

Info

Publication number
MX2016016756A
MX2016016756A MX2016016756A MX2016016756A MX2016016756A MX 2016016756 A MX2016016756 A MX 2016016756A MX 2016016756 A MX2016016756 A MX 2016016756A MX 2016016756 A MX2016016756 A MX 2016016756A MX 2016016756 A MX2016016756 A MX 2016016756A
Authority
MX
Mexico
Prior art keywords
endometrial
stem cell
cell therapy
pathologies
regeneration
Prior art date
Application number
MX2016016756A
Other languages
English (en)
Inventor
Pellicer Antonio
SIMÓN Carlos
Cervello Irene
SANTAMARIA Javier
Original Assignee
Igenomix S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igenomix S L filed Critical Igenomix S L
Publication of MX2016016756A publication Critical patent/MX2016016756A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Abstract

La presente invención se refiere generalmente a la habilidad de células madre derivadas de médula ósea de CD113+ autólogas (BMDSC) para inducir la regeneración del endometrio y tratar patologías endometriales tales como el síndrome de Asherman y atrofia endometrial; métodos para inducir la regeneración endometrial se proporcionan, los cuales comprenden la administración de una cantidad efectiva de células madre derivadas de médula ósea de CD133+ autólogas (BMDSC) en arterias uterinas de un sujeto en necesidad de las mismas para inducir la regeneración del endometrio.
MX2016016756A 2014-06-17 2015-06-05 Terapia con células madre en patologías endometriales. MX2016016756A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462013121P 2014-06-17 2014-06-17
PCT/IB2015/001715 WO2015193737A1 (en) 2014-06-17 2015-06-05 Stem cell therapy in endometrial pathologies

Publications (1)

Publication Number Publication Date
MX2016016756A true MX2016016756A (es) 2017-11-02

Family

ID=54329860

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016756A MX2016016756A (es) 2014-06-17 2015-06-05 Terapia con células madre en patologías endometriales.

Country Status (21)

Country Link
US (1) US11129851B2 (es)
EP (3) EP4012023B1 (es)
JP (2) JP6920062B2 (es)
CN (2) CN107073040A (es)
AU (1) AU2015275798B2 (es)
BR (1) BR112016029558A2 (es)
CA (1) CA2952559C (es)
CY (1) CY1122615T1 (es)
DK (2) DK3158057T3 (es)
ES (2) ES2910306T3 (es)
HR (2) HRP20220419T1 (es)
HU (2) HUE044823T2 (es)
LT (2) LT3158057T (es)
MX (1) MX2016016756A (es)
PL (2) PL3569697T3 (es)
PT (2) PT3158057T (es)
RS (2) RS59210B1 (es)
RU (1) RU2725006C2 (es)
SI (2) SI3569697T1 (es)
TR (1) TR201910410T4 (es)
WO (1) WO2015193737A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
ES2705237T3 (es) 2012-06-06 2019-03-22 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón
BR112015008255B1 (pt) 2012-10-12 2023-02-28 Inbiomotion S.L Métodos in vitro para diagnóstico ou prognóstico de metástase óssea em um indivíduo com câncer de próstata e método para classificar um indivíduo que sofre de câncer de próstata em uma coorte
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20160040247A1 (en) 2013-03-15 2016-02-11 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the diagnosis, prognosis, and tratment of cancer metastasis
EP4012023B1 (en) 2014-06-17 2024-05-15 Asherman Therapy, S.L. Stem cell therapy in endometrial pathologies
RU2699029C1 (ru) * 2018-12-10 2019-09-03 Частное образовательное учреждение дополнительного профессионального образования "Академия медицинского образования имени Федора Ивановича Иноземцева" (ЧОУ ДПО "Академия медицинского образования им. Ф.И. Иноземцева") Способ использования мезенхимальных стволовых клеток для улучшения состояния рубца на матке
RU2741621C1 (ru) * 2020-09-25 2021-01-28 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Способ лечения внутриматочных синехий
KR20230015832A (ko) 2021-07-23 2023-01-31 차의과학대학교 산학협력단 분리된 미토콘드리아를 유효성분으로 포함하는 아셔만 증후군 예방 또는 치료용 약학 조성물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0473612B1 (en) 1989-05-05 1996-07-31 Northern Sydney Area Health Service Fertility enhancement
US6979533B2 (en) 1992-06-12 2005-12-27 The Trustees Of The University Of Pennsylvania Determination of endometrial receptivity toward embryo implantation
CA2203718A1 (en) 1997-04-25 1998-10-25 University Of British Columbia Cadherin-11 as an indicator of viable pregnancy
IL127896A0 (en) 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
US6733962B2 (en) 2000-03-08 2004-05-11 Harvey J. Kliman Methods of diagnosing and monitoring endometrial glandular development
JP2004504275A (ja) 2000-05-24 2004-02-12 シエーリング　アクチエンゲゼルシャフト フィブリン−１の医薬用途
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
AUPR673001A0 (en) 2001-07-31 2001-08-23 Prince Henry's Institute Of Medical Research Pregnancy-related enzyme activity
DE10139874A1 (de) 2001-08-10 2003-04-30 Schering Ag Humane Mater-Proteine
GB0201284D0 (en) 2002-01-21 2002-03-06 Isis Innovation Screening methods for contraceptive and fertility agents
US20030186300A1 (en) 2002-03-20 2003-10-02 Ali Akoum Methods and products for modulation of reproductive processes and for diagnosis, prognostication and treatment of related conditions
WO2004061074A2 (en) 2002-05-14 2004-07-22 The Board Of Trustees Of The Leland Stanford Junior University Endometrial genes in endometrial disorders
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
ES2273061T3 (es) 2002-08-02 2007-05-01 Schering Aktiengesellschaft Agentes moduladores de receptores de progesterona con actividad antigonadotropa elevada para el control de fertilidad femenina y para la terapia por reemplazo hormonal.
AU2003303347A1 (en) 2002-12-21 2004-07-22 Universitat Leipzig Method and means for determining specific conditions or changes in the uterine epithelium and in the epithelium of other organs
EP1660228A1 (en) 2003-08-21 2006-05-31 PamGene B.V. Microarray support for bioprobe synthesis
JP2007504807A (ja) 2003-09-08 2007-03-08 ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 培養培地にプロスタグランジン又はプロスタグランジン類似物を補足することによってインビトロ胚発生を高めるための方法及び組成
EP1670902A4 (en) 2003-09-08 2008-05-07 Univ Texas METHOD AND COMPOSITION FOR ENHANCING IN VITRO EMBRYONIC DEVELOPMENT BY ENRICHING A CULTURE MEDIUM COMPRISING PROSTAGLANDIN OR PROSTAGLANDIN ANALOGUE
AU2004303448A1 (en) 2003-12-23 2005-07-07 Mount Sinai Hospital Methods for detecting markers associated with endometrial disease or phase
US20080014172A1 (en) 2004-05-28 2008-01-17 Applied Research Systems Ars Holding N.V. Use of Il-17 in the Treatment of Fertility-Related Disorders
US20090111140A1 (en) * 2006-03-31 2009-04-30 Koninklijke Philips Electronics N.V. Systems and methods for cell measurement utilizing ultrashort t2*
JP2007278750A (ja) 2006-04-04 2007-10-25 Ono Pharmaceut Co Ltd プロスタグランジン類及びその類縁体の定量方法
US20120269774A1 (en) * 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
GB0703683D0 (en) * 2007-02-26 2007-04-04 Ark Therapeutics Ltd The treatment of complications in pregnancy
US9259233B2 (en) * 2007-04-06 2016-02-16 Hologic, Inc. Method and device for distending a gynecological cavity
US8673850B2 (en) 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
WO2013166281A1 (en) * 2012-05-02 2013-11-07 Cedars-Sinai Medical Center Bi-functional compositions for targeting cells to diseased tissues and methods of using same
EP2348318A1 (en) 2010-01-21 2011-07-27 Equipo Ivi Investigación, S.L. Diagnostic method for endometrial receptivity
US9453259B2 (en) 2011-10-21 2016-09-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for assessing endometrial receptivity of a patient after controlled ovarian hyperstimulation
SG11201402649QA (en) 2011-11-30 2014-06-27 Agency Science Tech & Res Gm1 ganglioside to annexin v microparticle polypeptide ratio for biological monitoring
KR101996123B1 (ko) 2012-06-27 2019-07-03 에프. 호프만-라 로슈 아게 특정 시기 내에 임신중독증의 개시를 배제하기 위한 sFlt-1/PlGF 또는 엔도글린/PlGF 비의 적용 수단 및 방법
RU2515475C1 (ru) * 2012-11-15 2014-05-10 Федеральное государственное бюджетное учреждение науки ИНСТИТУТ ЦИТОЛОГИИ РОССИЙСКОЙ АКАДЕМИИ НАУК Способ стимуляции образования децидуальной оболочки эндометрия в эксперименте
CN106662589B (zh) 2014-03-21 2019-07-30 艾基诺米公司 先兆子痫的早期检测
EP4012023B1 (en) 2014-06-17 2024-05-15 Asherman Therapy, S.L. Stem cell therapy in endometrial pathologies

Also Published As

Publication number Publication date
RU2017101147A3 (es) 2019-02-06
PT3158057T (pt) 2019-07-19
PL3569697T3 (pl) 2022-07-04
RS59210B1 (sr) 2019-10-31
EP3158057A1 (en) 2017-04-26
SI3569697T1 (sl) 2022-05-31
ES2736117T3 (es) 2019-12-26
BR112016029558A2 (pt) 2017-08-22
CN116747241A (zh) 2023-09-15
RU2017101147A (ru) 2018-07-17
WO2015193737A1 (en) 2015-12-23
PL3158057T3 (pl) 2020-05-18
EP4012023B1 (en) 2024-05-15
TR201910410T4 (tr) 2019-08-21
DK3158057T3 (da) 2019-07-29
US11129851B2 (en) 2021-09-28
CN107073040A (zh) 2017-08-18
AU2015275798A1 (en) 2017-02-02
EP3158057B1 (en) 2019-04-17
DK3569697T3 (da) 2022-04-04
LT3158057T (lt) 2019-09-25
HRP20220419T1 (hr) 2022-05-27
EP3569697B8 (en) 2022-04-27
RS63093B1 (sr) 2022-04-29
EP3569697B1 (en) 2022-01-05
CA2952559A1 (en) 2015-12-23
HUE058328T2 (hu) 2022-07-28
JP2017522288A (ja) 2017-08-10
EP3569697A1 (en) 2019-11-20
JP2020138984A (ja) 2020-09-03
PT3569697T (pt) 2022-05-02
ES2910306T3 (es) 2022-05-12
LT3569697T (lt) 2022-04-25
CA2952559C (en) 2023-01-24
RU2725006C2 (ru) 2020-06-29
SI3158057T1 (sl) 2019-10-30
EP4012023A1 (en) 2022-06-15
US20170128492A1 (en) 2017-05-11
HRP20191240T1 (hr) 2019-11-01
JP6920062B2 (ja) 2021-08-18
HUE044823T2 (hu) 2019-11-28
CY1122615T1 (el) 2021-03-12
AU2015275798B2 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
MX2016016756A (es) Terapia con células madre en patologías endometriales.
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
PH12018500810A1 (en) Antibody agents specific for human cd19 and uses thereof
PH12017500803A1 (en) Anti-pd-1 antibodies
PH12017501342A1 (en) Glycan therapeutics and related methods thereof
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
GB2541571A (en) Pharmaceutical compositions
SG10201806108TA (en) Binding proteins and methods of use thereof
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
MX2021006734A (es) Metodo para tratar el cancer.
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX2018000897A (es) Celulas madre hematopoyeticas que expresan pd-l1 y usos.
MX2016004556A (es) Composicion de hueso comprimido y metodo para usar la misma.
NZ729417A (en) Compositions and methods for enhancing healing and regeneration of bone and soft tissue
MX359769B (es) Metodos para descelularizar huesos.
MX2013004061A (es) Analogos de ciclosporina.
MX2017014245A (es) Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas.
CR20200322A (es) Anticuerpos de cadena pesada que se unen a cd22
IN2014KN02620A (es)
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
AU2016356504A8 (en) 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
TW201613569A (en) Composition consisting of kukoamine A and/or kukoamine B and method of using thereof

Legal Events

Date Code Title Description
FG Grant or registration